ストックスクリーナーアプリを入手
0.6096
1.68%
-0.0104
アフターアワーズ：
.61
0.0004
+0.07%
前日終値:
$0.62
開ける：
$0.6273
24時間の取引高:
3.72M
Relative Volume:
1.71
時価総額：
$136.69M
収益：
-
当期純損益:
$-83.01M
株価収益率:
-1.2937
EPS:
-0.4712
ネットキャッシュフロー:
$-64.63M
1週間 パフォーマンス:
-10.26%
1か月 パフォーマンス:
-13.09%
6か月 パフォーマンス:
-15.61%
1年 パフォーマンス:
-59.09%
1日の値動き範囲:
$0.60
$0.64
1週間の範囲:
$0.60
$0.71
52週間の値動き範囲:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
名前
Tenaya Therapeutics Inc
セクター
電話
415-865-2066
住所
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.6096 | 136.69M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-10 | 開始されました | William Blair | Outperform |
| 2023-11-30 | 開始されました | Leerink Partners | Outperform |
| 2022-06-15 | 開始されました | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc (TNYA) 最新ニュース
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TENAYA THERAPEUTICS INC (TNYA) Stock Chart - ChartMill
Tenaya Therapeutics, Inc.(NasdaqCM: TNYA) added to S&P Global BMI Index - marketscreener.com
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - investingnews.com
Tenaya Therapeutics Grants 49,000 Shares to CMO Tingley Whittemore (NASDAQ: TNYA) - Kalkine Media
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics CEO Ali Faraz Receives 122,000 Shares and 732,500 Derivative Securities at No Cost (NASDAQ: TNYA) - Kalkine Media
More than 70,000 people in the U.S. are estimated to have a genetic heart condition. A gene therapy for it received special FDA status. - Stock Titan
Tenaya at H.C. Wainwright conference: gene therapy data build By Investing.com - Investing.com UK
A heart-disease biotech will meet investors at two September conferences - Stock Titan
Tenaya Therapeutics (TNYA) Stock Holds Near $0.69 Support Zone as Biotech Faces Key Technical TestMESA MA - siam.in
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - Barchart.com
Israel Englander group takes passive stake in Tenaya Therapeutics (TNYA) - stocktitan.net
Tenaya Therapeutics (TNYA) Falls 3.85% to $0.70 as Shares Approach Critical SupportSynthetic Long - vinanet.vn
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 - MarketBeat
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares By Investing.com - Investing.com Australia
Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock By Investing.com - Investing.com Nigeria
Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares - Investing.com
Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock - MarketBeat
Tenaya Therapeutics, Inc. SEC Filing (Aug 18, 2026) - Stock Titan
GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
Tenaya Therapeutics (NASDAQ: TNYA) CEO sells 22K shares to cover RSU taxes - Stock Titan
Tenaya Therapeutics (TNYA) Q2 2026 Earnings: EPS Misses by 186.94% as Clinical-Stage Pipeline Drives Wider-Than-Expected LossRevenue Recognition Risk - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Transcript : Tenaya Therapeutics, Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-11-2026 12 - marketscreener.com
Tenaya Therapeutics (TNYA) Institutional Ownership 2026 - MarketBeat
Tenaya Therapeutics (TNYA) Drops 4% to $0.73 — Testing Crucial Support ZoneADD Alert - Vinanet
TNYA Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Climb on Pipeline OptimismDiluted EPS Report - vinanet.vn
Tenaya Therapeutics at Canaccord Genuity conference: q4 catalysts loom By Investing.com - Investing.com Canada
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings - MarketBeat
Q3 Earnings Forecast for TNYA Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating - moomoo.com
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results - MarketBeat
Tenaya Therapeutics (TNYA) Gains 5.81% as Biotech Stock Holds Above Critical $0.74 SupportZero Gamma Level - dars.gov.et
Tenaya Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Tenaya Therapeutics Q2 net loss widens on impairment charge - TradingView
Tenaya Therapeutics (TNYA) Jumps 5.8% to $0.78 as It Tests Key Resistance at $0.82Calendar Spread Trade - dars.gov.et
Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday - MarketBeat
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Tenaya CFO Eric Hyllengren to Speak at Boston Conference - Stock Titan
Tenaya Therapeutics (TNYA) Steadies Above $0.70 Support as Trading Volume Signals Cautious SentimentStock News - careplusvn.com
Tenaya Therapeutics (TNYA) Slips to $0.74 as Key Support at $0.70 Comes into FocusMutual Fund Flow - careplusvn.com
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TNYA|Tenaya Therapeutics Inc|Price:0.769|Chg%:-0.006 - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenaya Therapeutics Inc (TNYA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):